Diphenylterazine (DTZ) is a bioluminescence agent. Diphenylterazine alone yielded very little background, leading to excellent signal-to-background ratios^[1].

Diphenylterazine elicits minimal cell toxicity at millimolar concentrations^[1].
Notes: To make a stock solution for DTZ (Diphenylterazine), first, a premixture is prepared by dissolving 17.6 mg of L-ascorbic acid (HY-B0166) in 10 mL ethanol and 10 mL 1,2-propanediol; next, 1 mg of DTZ is dissolved in 88 µL of the premix, resulting in a 30 mM DTZ stock solution containing 5 mM L-ascorbic acid^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Diphenylterazine injections into untransfected BALB/c mice do not yield any background emission. The bioluminescence resulting from intraperitoneally injected Diphenylterazine displays extended kinetics^[1].
DTZ (0.3 μmol/mouse (1.13 mg.ml^-1/100 ul/mouse); i.v.) treatment can track tumor growth in a xenograft NU/J mouse model^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

377.44

C₂₅H₁₉N₃O

344940-63-2

Room temperature in continental US; may vary elsewhere.

-80deg;C, protect from light

DMF : 11.11 mg/mL (29.44 mM; Need ultrasonic; DMSO can inactivate Diphenylterazine’s activity)

EtOH+HCl : 1 mg/mL (2.65 mM; ultrasonic and warming and adjust pH to 2 with 1M HCl and heat to 80°C; DMSO can inactivate Diphenylterazine’s activity)

H₂O : < 0.1 mg/mL (insoluble; DMSO can inactivate Diphenylterazine’s activity)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months (protect from light)。-80°C 储存时，请在 6 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂：;50% PEG300 ;; 50% saline

  Solubility: 2 mg/mL (5.30 mM); Suspended solution; Need ultrasonic
• 2.

  请依序添加每种溶剂：;10% DMF ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

  Solubility: ≥ 1.11 mg/mL (2.94 mM); Clear solution

• [1]. Yeh HW, et al. Red-shifted luciferase-luciferin pairs for enhanced bioluminescence imaging. Nat Methods. 2017 Oct;14(10):971-974.

  [2]. Hsien-Wei Yeh, et al. ATP-Independent Bioluminescent Reporter Variants To Improve in Vivo Imaging. ACS Chem Biol. 2019 May 17;14(5):959-965.

  [3]. Practical Notes for teLuc-DTZ and Antares2-DTZ (updated 07/29/2019).

BALB/c mice are used and transfected with cells expressing teLuc, Antares, Antares2 and FLuc by injecting cells into the tail vein of BALB/c mice. After the diminishing of the FLuc bioluminescence, 0.3 µmol Diphenylterazine or furimazine is intraperitoneally injected. Mice are imaged with a 1-min exposure per frame over a course of 20 min. The images are processed using the Fiji image analysis software and the frames with highest signals in individual experiments are used for comparison^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

• [1]. Yeh HW, et al. Red-shifted luciferase-luciferin pairs for enhanced bioluminescence imaging. Nat Methods. 2017 Oct;14(10):971-974.

  [2]. Hsien-Wei Yeh, et al. ATP-Independent Bioluminescent Reporter Variants To Improve in Vivo Imaging. ACS Chem Biol. 2019 May 17;14(5):959-965.

  [3]. Practical Notes for teLuc-DTZ and Antares2-DTZ (updated 07/29/2019).